Boston Scientific Reports Exceptional 2025 Revenue Growth Driven by Cardiovascular Innovation
- Boston Scientific credits innovation for 2025: Q4 net sales $5.286B (+15.9%), full‑year $20.074B (+19.9%).
- Growth concentrated in Cardiovascular: Q4 up 18.2% reported; MedSurg up 11.7%.
- Boston Scientific highlights continued R&D, disciplined operations, and discontinuing ACURATE neo2/Prime valves as portfolio strategy.
Boston Scientific credits innovation for exceptional 2025 revenue growth
Innovation Drives Cardiovascular-Led Revenue Surge
Boston Scientific posts fourth-quarter net sales of $5.286 billion, marking a 15.9% reported increase and a 12.7% organic rise versus a year earlier, and closes 2025 with full‑year net sales of $20.074 billion, up 19.9% reported and 15.8% organic. Management says reported fourth‑quarter sales exceed its guidance band and that global teams deliver differentiated innovation and execution that drive patient impact and market share gains. The company frames 2025 as an exceptional year that both outperforms targets and positions it for sustained growth.
The revenue performance is concentrated in the Cardiovascular franchise, which grows 18.2% reported and 16.1% organic in the quarter, while the MedSurg portfolio posts 11.7% reported growth and 6.5% organic growth. Regionally, the U.S. market expands 17.0% reported and operational, with EMEA advancing 12.4% reported and 4.8% operational. Boston Scientific points to new product introductions and continued commercial execution as key drivers of the cardiovascular strength and broader top‑line momentum across markets.
Executives underscore continued investment in research and development, disciplined operations and targeted product launches to sustain revenue and margin expansion. CEO Mike Mahoney emphasizes that innovation and performance are driving measurable patient impact and setting the company up for future growth. The company also notes a strategic product decision earlier in the year to discontinue worldwide sales of the ACURATE neo2™ and ACURATE Prime™ valves in Q2 2025, a move it presents as part of portfolio management and operational focus.
Earnings and guidance nuance
On profitability, Boston Scientific reports GAAP net income attributable to common stockholders of $672 million, or $0.45 per share, in the fourth quarter and $2.898 billion, or $1.94 per share, for the full year. Adjusted earnings per share for the quarter are $0.80, modestly above the company’s own adjusted guidance, while reported GAAP EPS slightly trails the prior guidance range.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

